Sartorius Opens New Application Center in Shanghai
Sartorius has officially opened a new application center at its Shanghai office. Among the guests, representatives from the Shanghai government, customers from the biopharmaceutical industry, as well as business partners and the media, attended the opening ceremony.
With a floor space of 240 square meters, or 2600 square feet, the new application center offers ample room for product demonstrations, trial runs and training sessions. At this center, customers from the biopharmaceutical industry can now test the latest Sartorius products for cell cultivation, media and buffer preparation, sterile filtration, cross-flow purification, membrane chromatography, virus clearance and aseptic processing. For laboratory customers, Sartorius showcases its entire range of lab instruments and consumables from balances, moisture analysers, pipettes and water purification systems to filters and products for microbiological testing and quality control.
In his speech, Michael Melingo, member of the Sartorius Group Executive Committee and in charge of marketing, sales and services of Sartorius’ lab business, underlined the importance of Shanghai as a strategic and geographical hub for Sartorius in Asia. “Located close to our customers’ R&D centers in Shanghai and other biotech hotspots like Seoul, Tokyo and Singapore, our application center is the place to be for top scientists to talk about the latest industrial and technological trends.” With the substantial investment in this new application center, Sartorius has further extended its footprint in Asia.
Dr Jörg Lindenblatt, the Senior Vice President of Sales Asia/Pacific for Bioprocess Solutions, emphasised the practical approach of the application center. “Our application center is not just a showroom for our extensive range of lab and bioprocess products. We invite our customers to gain hands-on experience with our
technologies during training and demonstration. By doing this, we can demonstrate the benefits of the high degree of seamless integration of the newest state-of-the-art technology for biotech manufacturing.” Besides being used for demonstration purposes, the new application center will serve as training facility for customers,
distributors and staff.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...